OBJECTIVE: To evaluate the Intermediate-term and long-term clinical results of Ahmed glaucoma valve (AGV) implantation in refractory glaucoma. METHODS: A retrospective study was conducted to document 221 eyes from 206 patients with refractory glaucoma who undergone AGV implantation or combined AGV implantation with other intraocular surgery. The subject had a minimum 6 months of follow-up after surgery. According to the successful definition of AGV implantation, life table's analysis was used to assess the cumulative probabilities of success in different follow-up time. Cox regression analysis was performed to estimate the relationships between survival outcomes and multiple predictors. RESULTS: The follow-up ranged from 6.03 to 86.30 months (mean 36.86 months). The cumulative probabilities of success at 0.5, 1, 2, 3, and 4 years were (88.5 +/- 2.2)%, (85.0 +/- 2.5)%, (76.4 +/- 3.1)%, (66.2 +/- 3.7)%, (55.5 +/- 4.7)% and of total success at 0.5, 1, 2, 3, and 4 years were (91.2 +/- 1.9)%, (88.6 +/- 2.2)%, (88.6 +/- 2.2)%, (86.8 +/- 2.5)%, (86.8 +/- 2.5)%, respectively. Intraocular pressure was reduced from a preoperative mean of (44.59 +/- 13.04) mm Hg (1 mm Hg = 0.133 kPa) to a postoperative mean of (16.52 +/- 4.61) mm Hg (P < 0.01). The early major complications included transient hypotony (19.5%), shallow anterior chamber (14.5%), tube blockage (11.3%), hemorrhage (7.2%). The late major complications were encapsulated bleb (10.9%), exposure of tube (5.0%), tube malposition (4.5%), corneal decompensation (2.3%), extrusion of implant (1.4%). CONCLUSIONS: AGV or combined AGV with other intraocular surgery is effective and relatively safe method for treating refractory glaucoma. The rates of success can be increased by means of effective management of the complications.
OBJECTIVE: To evaluate the Intermediate-term and long-term clinical results of Ahmed glaucoma valve (AGV) implantation in refractory glaucoma. METHODS: A retrospective study was conducted to document 221 eyes from 206 patients with refractory glaucoma who undergone AGV implantation or combined AGV implantation with other intraocular surgery. The subject had a minimum 6 months of follow-up after surgery. According to the successful definition of AGV implantation, life table's analysis was used to assess the cumulative probabilities of success in different follow-up time. Cox regression analysis was performed to estimate the relationships between survival outcomes and multiple predictors. RESULTS: The follow-up ranged from 6.03 to 86.30 months (mean 36.86 months). The cumulative probabilities of success at 0.5, 1, 2, 3, and 4 years were (88.5 +/- 2.2)%, (85.0 +/- 2.5)%, (76.4 +/- 3.1)%, (66.2 +/- 3.7)%, (55.5 +/- 4.7)% and of total success at 0.5, 1, 2, 3, and 4 years were (91.2 +/- 1.9)%, (88.6 +/- 2.2)%, (88.6 +/- 2.2)%, (86.8 +/- 2.5)%, (86.8 +/- 2.5)%, respectively. Intraocular pressure was reduced from a preoperative mean of (44.59 +/- 13.04) mm Hg (1 mm Hg = 0.133 kPa) to a postoperative mean of (16.52 +/- 4.61) mm Hg (P < 0.01). The early major complications included transient hypotony (19.5%), shallow anterior chamber (14.5%), tube blockage (11.3%), hemorrhage (7.2%). The late major complications were encapsulated bleb (10.9%), exposure of tube (5.0%), tube malposition (4.5%), corneal decompensation (2.3%), extrusion of implant (1.4%). CONCLUSIONS: AGV or combined AGV with other intraocular surgery is effective and relatively safe method for treating refractory glaucoma. The rates of success can be increased by means of effective management of the complications.
Authors: Vishnu S Gupta; Harinder S Sethi; Malvika Gupta; Anuj Mehta; Shivram Singh; Pankaj Yadav; K P S Malik Journal: BMC Ophthalmol Date: 2010-09-17 Impact factor: 2.209